CytoDyn Announces Investor Call to Provide Update on Clinical Development Strategy
May 15, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Wash., May 15, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency...
CytoDyn Inc. Announces First HIV Patient Dosing With PRO 140 in Phase 2b Clinical Trial for Treatment Substitution Protocol
May 14, 2014 08:00 ET
|
CytoDyn
VANCOUVER, Wash., May 14, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency...
CytoDyn to Develop Nonsynthetic Cancer Drug
March 28, 2006 09:00 ET
|
CytoDyn
SANTE FE, N.M., March 28, 2006 (PRIMEZONE) -- CytoDyn, Inc. (OTCBB:CYDY), best known for Cytolin(r), a targeted immune therapy for treating HIV/AIDS, has announced plans to develop a nonsynthetic...
CytoDyn Applies for Cancer Drug Trademark: Formaxycin
March 27, 2006 09:00 ET
|
CytoDyn
SANTA FE, N.M., March 27, 2006 (PRIMEZONE) -- CytoDyn, Inc. (OTCBB:CYDY) has applied for the trademark Formaxycin(tm) (fer-MAX-uh-sin) to brand its new cancer drug. Like several approved cancer drugs,...
CytoDyn CEO Explains Company's Strategy to Prevent Drug-Resistant Germs
March 20, 2006 09:00 ET
|
CytoDyn
ALBUQUERQUE, N.M., March 20, 2006 (PRIMEZONE) -- A recent meeting of the New Mexico Biotechnology & Biomedical Association featured a talk by Allen D. Allen, CEO of CytoDyn, Inc. (OTCBB:CYDY)....